IO Biotech will provide corporate updates at two investor conferences in September 2025 regarding its cancer vaccine development.
Quiver AI Summary
IO Biotech, a clinical-stage biopharmaceutical company specializing in immune-modulatory cancer vaccines, has announced that its senior management will provide updates and engage in one-on-one meetings at two upcoming investor conferences in New York. The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025. IO Biotech is advancing its investigational therapeutic cancer vaccine candidate Cylembio®, which is currently being studied in pivotal and Phase 2 clinical trials in collaboration with Merck. The company emphasizes its commitment to developing innovative cancer treatments through its T-win® platform and is based in Copenhagen with a U.S. headquarters in New York.
Potential Positives
- IO Biotech will present at two significant investor conferences, increasing visibility and engagement with potential investors and stakeholders.
- The company is advancing its lead cancer vaccine candidate, Cylembio®, which is currently undergoing pivotal Phase 3 trials, indicating progress in its clinical development.
- Enrollment in the Phase 3 trial was completed rapidly, demonstrating efficient clinical operations and potentially expediting the pathway to market.
- IO Biotech retains global commercial rights to Cylembio, providing them with full control over the commercialization strategy for this promising drug candidate.
Potential Negatives
- There is a lack of substantive data or outcomes shared regarding the ongoing clinical trials, which could lead to investor skepticism about the effectiveness of the company's lead product, Cylembio.
- The reliance on forward-looking statements introduces significant uncertainty regarding regulatory and market outcomes, which may negatively impact investor confidence.
- The press release includes a disclaimer stating that forward-looking statements may differ materially from actual results, potentially creating apprehension about the company's ability to achieve its stated goals.
FAQ
What is Cylembio®?
Cylembio® is an investigational cancer vaccine candidate designed to target tumor and immune-suppressive cells in the tumor microenvironment.
When will IO Biotech present at investor conferences?
IO Biotech will present at the Morgan Stanley conference on September 9, 2025, and at H.C. Wainwright on September 10, 2025.
How can I access the webcast of the presentations?
The webcast replay will be available for 90 days on IO Biotech's Investors website section at https://investors.iobiotech.com.
What trials is IO Biotech conducting for Cylembio®?
IO Biotech is conducting a Phase 3 trial and two Phase 2 trials of Cylembio® in various combinations with pembrolizumab.
Where is IO Biotech headquartered?
IO Biotech is headquartered in Copenhagen, Denmark, with a US office located in New York, New York.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IOBT Insider Trading Activity
$IOBT insiders have traded $IOBT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IOBT stock by insiders over the last 6 months:
- HEIDI HUNTER purchased 15,000 shares for an estimated $20,884
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IOBT Hedge Fund Activity
We have seen 10 institutional investors add shares of $IOBT stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PFM HEALTH SCIENCES, LP removed 369,034 shares (-15.8%) from their portfolio in Q2 2025, for an estimated $512,957
- DAUNTLESS INVESTMENT GROUP, LLC removed 357,057 shares (-52.4%) from their portfolio in Q2 2025, for an estimated $496,309
- MORGAN STANLEY removed 135,783 shares (-17.2%) from their portfolio in Q2 2025, for an estimated $188,738
- ROYAL BANK OF CANADA removed 60,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $65,400
- LANDSCAPE CAPITAL MANAGEMENT, L.L.C. removed 52,826 shares (-13.2%) from their portfolio in Q2 2025, for an estimated $73,428
- BANK OF AMERICA CORP /DE/ removed 36,441 shares (-2.2%) from their portfolio in Q2 2025, for an estimated $50,652
- NEWEDGE ADVISORS, LLC added 24,217 shares (+inf%) to their portfolio in Q2 2025, for an estimated $33,661
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IOBT Analyst Ratings
Wall Street analysts have issued reports on $IOBT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 08/12/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/01/2025
To track analyst ratings and price targets for $IOBT, check out Quiver Quantitative's $IOBT forecast page.
$IOBT Price Targets
Multiple analysts have issued price targets for $IOBT recently. We have seen 2 analysts offer price targets for $IOBT in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $4.0 on 08/12/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $12.0 on 04/01/2025
Full Release
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following upcoming investor conferences:
Event: Morgan Stanley 23
rd
Annual Global Healthcare Conference
Location: New York, New York
Fireside Chat Date & Time: Tuesday, September 9, 2025 at 7:45 am ET
Presenters: Mai-Britt Zocca, PhD, President and CEO, Amy Sullivan, CFO, and Qasim Ahmad, MD, CMO
Webcast Link:
Here
Event: H.C. Wainwright 27
th
Annual Global Investment Conference
Location: New York, New York
Presentation Date & Time: Wednesday, September 10, 2025 at 8:00 am ET
Presenter: Mai-Britt Zocca, PhD, President and CEO
Webcast Link:
Here
The webcast replay for the fireside chat and the presentation will be available from the Investors section of the company’s website at https://investors.iobiotech.com for 90 days.
About Cylembio ®
Cylembio ® (imsapepimut and etimupepimut, adjuvanted) is an investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine candidate designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase 1 (IDO1) positive and/or programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating Cylembio in combination with Merck’s anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab) versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating Cylembio in combination with pembrolizumab as first line treatment in patients with advanced solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating Cylembio in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors. Enrollment in the Phase 3 trial was completed rapidly by December 2023 with topline results from this trial reported in the third quarter of 2025. Enrollment in the two ongoing company-sponsored Phase 2 clinical trials is now complete.
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio.
Cylembio ® is a registered trademark of IO Biotech ApS, a subsidiary of IO Biotech.
KEYTRUDA ® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the US and Canada).
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win ® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio ® , in clinical trials, and additional pipeline candidates through preclinical development. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com . Follow us on our social media channels on LinkedIn and X ( @IOBiotech ).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including statements regarding the timing or outcome of communications with regulatory authorities including the FDA, the timing or outcome of the submission of marketing applications, including a BLA, for Cylembio, the timing or outcome of the launch of Cylembio, and statements regarding other current or future clinical trials, their timing, progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
[email protected]
Media
Julie Funesti
Edelman
917-498-1967
[email protected]
